Stereotactic body radiotherapy for lung cancer: How much does it really cost?

Journal of Thoracic Oncology

Volumn 10, Issue 3, 2015, Pages 454-461

  Lievens, Yolande ^a   Obyn, Caroline ^b   Mertens, Anne Sophie ^c   Halewyck, Dries Van ^c   Hulstaert, Frank ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c Möbius NV SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BELGIAN; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DEVICE ECONOMICS; DEVICE MAINTENANCE; EXTERNAL BEAM RADIOTHERAPY; FACE MASK; FIDUCIAL MARKER; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE COST; INTENSITY MODULATED RADIATION THERAPY; LEARNING CURVE; LINEAR ACCELERATOR; LUNG CANCER; MEDICAL FEE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION ONCOLOGIST; RADIOTHERAPY PLANNING SYSTEM; RADIOTHERAPY SIMULATOR; REIMBURSEMENT; STEREOTACTIC BODY RADIATION THERAPY; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; LUNG NEOPLASMS; MULTICENTER STUDY; PROGNOSIS; RADIOSURGERY;

COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84938294097     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000421     Document Type: Article

References (19)

1. De Ruysscher D, Faivre-Finn C, Nestle U, European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010 28 5301 5310
2. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P, Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-Analysis. Radiother Oncol 2010 95 32 40
3. Wallner PE, Konski A, A changing paradigm in the study and adoption of emerging health care technologies: Coverage with evidence development. J Am Coll Radiol 2008 5 1125 1129
4. Walker S, Sculpher M, Claxton K, Palmer S, Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health 2012 15 570 579
5. Hulstaert F, Mertens A-S, Obyn C, Innovative radiotherapy techniques: a multicentre time-driven activity-based costing study. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE) KCE Reports. Brussels: Belgian Health Care Knowledge Centre (KCE) 2013. https://kce.fgov.be/sites/default/files/page-documents/kce-158c-innovative-high-risk-medical-devices-0.pdf. Accessed August 14, 2014
6. Cooper R, Kaplan RS, The Design of Cost Management Systems: Text, Cases, and Readings 1991 Englewood Cliffs, NJ Prentice Hall
7. Kaplan RS, Anderson SR, Time-driven activity-based costing. Harv Bus Rev 2004 82 131 8 150
8. Lievens Y, van den Bogaert W, Kesteloot K, Activity-based costing: A practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003 57 522 535
9. Van de Werf E, Verstraete J, Lievens Y, The cost of radiotherapy in a decade of technology evolution. Radiother Oncol 2012 102 148 153
10. Swartenbroekx N, Obyn C, Guillaume P, Manual for cost-based pricing of hospital interventions. KCE Reports 2012 Brussels Belgian Health Care Knowledge Centre (KCE). https://kce.fgov.be/sites/default/files/page-documents/KCE-178C-manual-pricing-hospital-interventions.pdf
11. Sher DJ, Wee JO, Punglia RS, Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011 81 e767 e774
12. Puri V, Crabtree TD, Kymes S, A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: A decision analysis. J Thorac Cardiovasc Surg 2012 143 428 436
13. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM, Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 2011 34 494 498
14. Jacobs BL, Zhang Y, Skolarus TA, Hollenbeck BK, Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) 2012 31 750 759
15. Lievens Y, Kesteloot K, Rijnders A, Kutcher G, Van den Bogaert W, Differences in palliative radiotherapy for bone metastases within Western European countries. Radiother Oncol 2000 56 297 303
16. Fairchild A, Barnes E, Ghosh S, International patterns of practice in palliative radiotherapy for painful bone metastases: Evidence-based practice? Int J Radiat Oncol Biol Phys 2009 75 1501 1510
17. van Loon J, Grutters J, Macbeth F, Evaluation of novel radiotherapy technologies: What evidence is needed to assess their clinical and cost effectiveness, and how should we get it? Lancet Oncol 2012 13 e169 e177
18. Peeters A, Grutters JP, Pijls-Johannesma M, How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 2010 95 45 53
19. Griffiths A, Marinovich L, Barton MB, Lord SJ, Cost analysis of Gamma Knife stereotactic radiosurgery. Int J Technol Assess Health Care 2007 23 488 494